Search for content and authors
 

Application of amylose tris(3,5dimethylphenyl- carbamate) chiral stationary phase for the determination of paroxetine, clinically used psychotropic drug

Małgorzata Lisowska Kuźmicz 1Agnieszka Ocios-Bębenek 1Małgorzata Kantor-Boruta 1Anna Jończyk 1Małgorzata Jarończyk 1Aleksander P. Mazurek 1,2Zdzisław Chilmonczyk 1

1. Narodowy Instytut Lekow (NIL), Chełmska 30/34, Warszawa 00-725, Poland
2. Medical University of Warsaw, Department of Drug Chemistry, Banacha 1, Warszawa 02-097, Poland

Abstract

Paroxetine {(-)-(3S,4R)-3-[(1,3-benzodioxol-5-yloxy)methyl]-4-(4-fluorophenyl)piperidine]} is a potent, selective serotonin reuptke inhibitor exhibiting minor affinity to muscarinic and cholinergic receptors. In clinics it is mainly used in major depression, anxiety and obsessive-compulsive disorders. In pharmaceutical preparations - beside (-)-trans-paroxetine (I) - (+)-trans-paroxetine, its probably inactive enantiomer [1], may be present.

Here we report validated analytical procedure enabling determination of (+/-)-trans-paroxetine  in medicinal products containing (+)-trans-paroxetine as a main active ingredient with the aid of amylose tris(3,5dimethylphenylcarbamate) chiral stationary phase. Validation included: specificity, linearity, limit of detection (LOD), limit of quantification (LOQ), assay, precision and recovery.

1. Segura M., Roura L., de la Torre R., Joglar J.; Synthesis of the major metabolites
of paroxetine, Bioorg. Chem. 31, 248-258 (2003).

 

Legal notice
  • Legal notice:
 

Related papers

Presentation: Poster at VIII Multidyscyplinarna Konferencja Nauki o Leku, by Małgorzata Lisowska Kuźmicz
See On-line Journal of VIII Multidyscyplinarna Konferencja Nauki o Leku

Submitted: 2012-03-14 10:06
Revised:   2012-05-10 00:27